Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate [Yahoo! Finance]
Immatics N.V. - Ordinary Shares (IMTX)
Company Research
Source: Yahoo! Finance
Immatics N.V. (NASDAQ: IMTX ) is among the best German stocks to buy according to analysts . On March 5, Immatics N.V. (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also provided updates on its business. Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate On the financial part, the company reported revenue of $56.8 million, compared to revenue of $183.1 million in 2024. For the revenue change, the management explained that in 2024, there was a one-time non-cash revenue tied to the company's deal with Bristol Myers Squibb. Turning to the bottom line, the company posted a net loss of $230.8 million in 2025, which compared with a net profit of $17.9 million in 2024. The management said the loss was caused by lower non-cash revenue and higher costs associated with advancement of clinical programs. On business update, Immatics N.V. said Phase 3 SUPRAME trial for its compound called anzu-cel (IMA203) was ongoing,
Show less
Read more
Impact Snapshot
Event Time:
IMTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMTX alerts
High impacting Immatics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
IMTX
News
- Immatics (IMTX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside [Yahoo! Finance]Yahoo! Finance
- Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot [Seeking Alpha]Seeking Alpha
- Immatics (IMTX) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold"MarketBeat
- Immatics Announces Full Year 2025 Financial Results and Business Update [Yahoo! Finance]Yahoo! Finance
IMTX
Earnings
- 11/17/25 - Beat
IMTX
Sec Filings
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- 3/18/26 - Form 3
- IMTX's page on the SEC website